Rare Disease Pipeline
Various Rare Conditions
Phase 2Active
Key Facts
About Swedish Orphan Biovitrum
Swedish Orphan Biovitrum AB (Sobi) is a publicly-traded Swedish specialty pharmaceutical company dedicated to rare diseases, hematology, immunology, and specialty care. With a market valuation of approximately $13.3 billion, Sobi has built a strong commercial portfolio including treatments for hemophilia, primary immunodeficiencies, and other rare conditions. The company combines in-house R&D capabilities with strategic partnerships and acquisitions to advance innovative therapies from development through commercialization.
View full company profile